Bayer's Amikacin Inhale Fails to Meet Objectives in Phase 3 Trial
November 24 2017 - 3:46AM
Dow Jones News
By Sonia Amaral Rohter
Bayer AG (BAYN.XE) said on Friday that Amikacin Inhale, an
integrated drug-device combination being tested in patients with a
type of pneumonia, failed to meet the primary objective in a phase
3 trial.
The trial was studying Amikacin Inhale in intubated and
mechanically ventilated patients with Gram-negative pneumonia. In
the study, Amikacin Inhale failed to demonstrate superiority over
the placebo and therefore did not meet either the primary or
secondary objectives of the trial. Amikacin Inhale is a drug-device
combination product that combines a specially formulated version of
the antibiotic amikacin with an inhalation system developed by
Nektar Therapeutics (NKTR) to deliver the drug to the patient's
lungs.
The Amikacin Inhale program is being developed through a
collaboration with Nektar Therapeutics.
Write to Sonia Amaral Rohter at
sonia.amaralrohter@dowjones.com
(END) Dow Jones Newswires
November 24, 2017 03:31 ET (08:31 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Apr 2023 to Apr 2024